Sentences with phrase «of allogeneic donor»

Initially, and during the first 10 - 15 years of cord blood transplantation, cord blood was predominantly used as a source of allogeneic donor cells.

Not exact matches

HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to - treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.

Of these 34 patients, 13 (38 %) have remained in remission for five years, and an additional two patients whose disease did not progress after BV went on to achieve remission after receiving allogeneic stem cell transplant (in which healthy stem cells are taken from a donor and administered to the patient).

While an important proof - of - principle, few individuals could benefit from allogeneic ccr5Δ32 homozygous transplants due to toxicities of allogeneic rejection and limitations of finding sufficient HLA - matched ccr5Δ32 homozygous donors.

Mehta J, Gordon LI, Tallman MS, et al., Does younger donor age affect the outcome of reduced - intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Allogeneic Sibling Donor Peripheral Blood Stem Cells Transplantation With Myeloablative Conditioning for Chronic Myeloid Leukemia in Blast Crisis - Successful Treatment Despite Severe Phase of the Disease

Horwitz et al 79 reported that donor MSC contributed to bone remodelling after allogeneic stem cell transplantation (SCT) in 3 children with osteogenesis imperfecta, a rare genetic disorder of type I collagen.

Allogeneic cells obtained from a donor organism of the same species.

In the future, outpatient blood and bone marrow stem cell transplantation will be offered to a broader group of patients with other blood disorders and for allogeneic transplants (transplant from non-twin donor stem cells).

Use of a lower dose of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor, according to the results of a study published in Lancet Oncology.

Allogeneic stem cell transplantation to leukaemic patients, in which the patient's own diseased bone marrow is replaced by healthy donor material, is one of the best - established and most effective immunological therapies.

Allogeneic cell transplantation enables the use of «younger» cells, from fetal origins (e.g., umbilical cord blood, placenta) or healthy donors, which are considered to be effective due to higher regenerative potential and plasticity.

Patients receive one of two types of stem cell - based transplants: autologous, in which a patient donates and receives back his / her own stem cells; or allogeneic, in which bone marrow - derived stem cells come from a related or unrelated donor whose human leukocyte antigens (HLA) are genetically matched with those of a patient.

(A and B) Flow cytometry analysis of intracellular IFN - γ and IL - 17A on donor - derived CD4 + T cells from spleen on indicated days for syngeneic and allogeneic mice.

Low - Dose ATLG Prevents GVHD in Pediatric Hematologic Malignancies: A newly published randomized phase III study of pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation from an unrelated donor.

Allogeneic cell therapies from primary cells for immunotherapy applications are especially challenging because of the vigor with which tissue donors must be screened and qualified to prevent transmission of infectious disease and ensure maintenance of an active donor pool.

This is the first time that in vitro generated HPCs were transplanted and used to establish long - term engraftment in allogeneic immunocompetent mice, resulting in the protection of donor type grafts from immunological rejection.

Thus, one can transplant fully allogeneic hematopoietic stem cells and co-transplant, for example, hearts from the hematopoietic stem cell donor to induce lifelong donor - specific acceptance of the transplant, without deleterious immunosuppression [4].

It offers to the commercialization of unrelated donor - patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.